Sanofi to build new facility in Canada to boost influenza vaccine supply

  • Sanofi (NASDAQ:SNY) announces an investment of more than €600 million in a new vaccine manufacturing facility at its existing site in Toronto, Canada.
  • The investment in a new facility will provide additional antigen and filling capacity for Sanofi's Fluzone High-Dose Quadrivalent influenza vaccine, helping to increase supply availability in Canada, the United States and Europe.
  • Sanofi expects this new facility to be operational in 2026, following design, construction, testing and qualification of the facility and equipment.
  • The fluzone High-Dose Quadrivalent influenza vaccine is currently manufactured exclusively by Sanofi Pasteur, Sanofi's vaccines global business unit, at its Swiftwater, Pennsylvania Site in the United States.

    For this year the company, located in Parijs revenue will be around 37.58 billion euros. This is according to the average of the analysts' estimates. This is slightly more than 2020's revenue of 37.37 billion euros.

    Historical revenues and results Sanofi-Aventis plus estimates 2020

    historische koersen

    The analysts expect for 2021 a net profit of 7.78 billion euros. For this year the consensus of the result per share is a profit of 6.11 euros. With this the price/earnings-ratio is 13.78.

    Huge dividend Sanofi-Aventis

    Per share the analysts expect a dividend of 3.3 euros per share. Thus the dividend yield equals 3.92 percent. The average dividend yield of the pharmaceutical companies is a limited 0.72 percent.

    Latest estimates around 94 euros

    Credit Suisse , Barclays and Goldman Sachs recently provided recommendations for the stock.

    Sanofi-Aventis 's market capitalization is based on the number of outstanding shares around 105.57 billion euros. The Sanofi-Aventis stock was the past 12 months quite volatile. Since last April the stock is 10 percent higher. This year the stock price moved between 75 and 96 euro.

    Historical stock prices Sanofi-Aventis

    stock sanofi-aventis

    On Thursday, the stock closed at 84.2 euros.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.